Breast Cancer Cell Density: Imaging assay of the density- and context-dependence of small molecule perturbagen response in breast cancer cell lines. Dataset 1 of 3: Cell count and normalized growth rate inhibition values. - Dataset (ID:20256)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | Replicate | Seeding Density | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | Linsitinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 92.00 | 130.25 | 0.7063 | -0.0079 |
| SK-BR-3 | Lapatinib | 0.01 | uM | 9 | 156.25 | 92.36 | 120.00 | 130.25 | 0.9213 | 0.6953 |
| SK-BR-3 | 17-AAG | 0.031623 | uM | 9 | 156.25 | 92.36 | 33.00 | 130.25 | 0.2534 | -0.8745 |
| SK-BR-3 | Lapatinib | 0.1 | uM | 9 | 156.25 | 92.36 | 96.00 | 130.25 | 0.7370 | 0.0810 |
| SK-BR-3 | Erlotinib | 0.31623 | uM | 9 | 156.25 | 92.36 | 192.00 | 130.25 | 1.4741 | 3.3739 |
| SK-BR-3 | Linsitinib | 0.31623 | uM | 9 | 156.25 | 92.36 | 174.00 | 130.25 | 1.3359 | 2.5864 |
| SK-BR-3 | Lapatinib | 0.0016596 | uM | 9 | 156.25 | 92.36 | 130.00 | 130.25 | 0.9981 | 0.9923 |
| SK-BR-3 | 17-AAG | 0.01 | uM | 9 | 156.25 | 92.36 | 92.00 | 130.25 | 0.7063 | -0.0079 |
| SK-BR-3 | Lapatinib | 0.031623 | uM | 9 | 156.25 | 92.36 | 110.00 | 130.25 | 0.8445 | 0.4225 |
| SK-BR-3 | Lapatinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 134.00 | 130.25 | 1.0288 | 1.1178 |
| SK-BR-3 | 17-AAG | 0.1 | uM | 9 | 156.25 | 92.36 | 61.00 | 130.25 | 0.4683 | -0.5668 |
| SK-BR-3 | Linsitinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 106.00 | 130.25 | 0.8138 | 0.3201 |
| SK-BR-3 | Linsitinib | 3.1623 | uM | 9 | 156.25 | 92.36 | 108.00 | 130.25 | 0.8292 | 0.3708 |
| SK-BR-3 | Erlotinib | 0.0033113 | uM | 9 | 156.25 | 92.36 | 101.00 | 130.25 | 0.7754 | 0.1975 |
| SK-BR-3 | Lapatinib | 1 | uM | 9 | 156.25 | 92.36 | 60.00 | 130.25 | 0.4607 | -0.5810 |
| SK-BR-3 | 0 | uM | 9 | 156.25 | 92.36 | 145.00 | 130.25 | 1.1132 | 1.4830 | |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 303.00 | 286.50 | 1.0576 | 1.2297 | |
| SK-BR-3 | Linsitinib | 0.1 | uM | 9 | 312.50 | 200.50 | 364.00 | 286.50 | 1.2705 | 2.1839 |
| SK-BR-3 | Lapatinib | 3.1623 | uM | 9 | 312.50 | 200.50 | 142.00 | 286.50 | 0.4956 | -0.4883 |
| SK-BR-3 | Linsitinib | 10 | uM | 9 | 312.50 | 200.50 | 332.00 | 286.50 | 1.1588 | 1.6628 |
| SK-BR-3 | Erlotinib | 0.1 | uM | 9 | 312.50 | 200.50 | 396.00 | 286.50 | 1.3822 | 2.7499 |
| SK-BR-3 | Erlotinib | 19.9526 | uM | 9 | 312.50 | 200.50 | 424.00 | 286.50 | 1.4799 | 3.2819 |
| SK-BR-3 | Erlotinib | 1 | uM | 9 | 312.50 | 200.50 | 315.00 | 286.50 | 1.0995 | 1.4044 |
| SK-BR-3 | 17-AAG | 0.0031623 | uM | 9 | 312.50 | 200.50 | 348.00 | 286.50 | 1.2147 | 1.9177 |
| SK-BR-3 | 0 | uM | 9 | 312.50 | 200.50 | 357.00 | 286.50 | 1.2461 | 2.0660 |